FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2610030900> ?p ?o ?g. }

• W2610030900 endingPage "1246" @default.
• W2610030900 startingPage "1237" @default.
• W2610030900 abstract "Objective Despite advances in cervical cancer prevention and diagnosis, outcomes for patients given a diagnosis of advanced and recurrent disease are poor. In the GOG240 trial, the addition of bevacizumab to paclitaxel-topotecan or paclitaxel-cisplatin has been shown to prolong survival compared with paclitaxel-topotecan or paclitaxel-cisplatin in patients with persistent, recurrent, or metastatic disease. However, standards of care vary between regions and countries. The purpose of this systematic review and network meta-analysis was to enable a comparison between bevacizumab + chemotherapy with multiple monotherapy or combination chemotherapy regimens in the treatment for women with advanced, recurrent, or persistent cervical cancer. Methods/Materials A systematic literature review was conducted to identify randomized or nonrandomized controlled trials of patients with recurrent, persistent, or metastatic cervical cancer published in English from 1999 to 2015. A feasibility study was performed to assess the heterogeneity of the trials, and a network meta-analysis was conducted. Fixed- and random-effects models were fitted to calculate the hazard ratio for overall survival (OS) for all pairwise comparisons and ranking of all interventions. Results Twenty-three studies (19 trials) met inclusion criteria and were included in the review. Sample sizes ranged from 69 to 452, and median patient age ranged from 45 to 53 years. There was a trend toward prolonged OS with cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab compared with all non–bevacizumab-containing therapies. Cisplatin-paclitaxel-bevacizumab had the highest probability of being the most efficacious compared with all regimens (68.1%), and cisplatin monotherapy had the lowest (0%). Conclusions The results of this network meta-analysis show that bevacizumab in combination with paclitaxel-topotecan or paclitaxel-cisplatin is likely to prolong OS over other non–bevacizumab-containing chemotherapies (eg, paclitaxel-carboplatin), which were not included in the GOG240 trial. In patients with advanced, persistent, and recurrent cervical cancer, cisplatin-paclitaxel-bevacizumab and topotecan-paclitaxel-bevacizumab showed the highest efficacy in all regimens investigated in this analysis." @default.
• W2610030900 created "2017-05-05" @default.
• W2610030900 creator A5027381322 @default.
• W2610030900 creator A5035698039 @default.
• W2610030900 creator A5053361502 @default.
• W2610030900 creator A5060765033 @default.
• W2610030900 creator A5066979556 @default.
• W2610030900 creator A5080632338 @default.
• W2610030900 creator A5087135665 @default.
• W2610030900 date "2017-07-01" @default.
• W2610030900 modified "2023-10-12" @default.
• W2610030900 title "Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer" @default.
• W2610030900 cites W1517555081 @default.
• W2610030900 cites W1554135143 @default.
• W2610030900 cites W1857980043 @default.
• W2610030900 cites W1987940634 @default.
• W2610030900 cites W2004732318 @default.
• W2610030900 cites W2005947177 @default.
• W2610030900 cites W2006699289 @default.
• W2610030900 cites W2040935111 @default.
• W2610030900 cites W2056913348 @default.
• W2610030900 cites W2079730922 @default.
• W2610030900 cites W2085996089 @default.
• W2610030900 cites W2087493660 @default.
• W2610030900 cites W2090031841 @default.
• W2610030900 cites W2100756525 @default.
• W2610030900 cites W2113144077 @default.
• W2610030900 cites W2118002846 @default.
• W2610030900 cites W2118508302 @default.
• W2610030900 cites W2126768246 @default.
• W2610030900 cites W2126834211 @default.
• W2610030900 cites W2129763891 @default.
• W2610030900 cites W2130406768 @default.
• W2610030900 cites W2138550445 @default.
• W2610030900 cites W2170781431 @default.
• W2610030900 cites W2171725862 @default.
• W2610030900 cites W2193377680 @default.
• W2610030900 cites W2289028990 @default.
• W2610030900 cites W2302752317 @default.
• W2610030900 cites W295024213 @default.
• W2610030900 cites W2966628446 @default.
• W2610030900 cites W4235291626 @default.
• W2610030900 cites W4243919243 @default.
• W2610030900 doi "https://doi.org/10.1097/igc.0000000000001000" @default.
• W2610030900 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5499964" @default.
• W2610030900 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28448304" @default.
• W2610030900 hasPublicationYear "2017" @default.
• W2610030900 type Work @default.
• W2610030900 sameAs 2610030900 @default.
• W2610030900 citedByCount "55" @default.
• W2610030900 countsByYear W26100309002017 @default.
• W2610030900 countsByYear W26100309002018 @default.
• W2610030900 countsByYear W26100309002019 @default.
• W2610030900 countsByYear W26100309002020 @default.
• W2610030900 countsByYear W26100309002021 @default.
• W2610030900 countsByYear W26100309002022 @default.
• W2610030900 countsByYear W26100309002023 @default.
• W2610030900 crossrefType "journal-article" @default.
• W2610030900 hasAuthorship W2610030900A5027381322 @default.
• W2610030900 hasAuthorship W2610030900A5035698039 @default.
• W2610030900 hasAuthorship W2610030900A5053361502 @default.
• W2610030900 hasAuthorship W2610030900A5060765033 @default.
• W2610030900 hasAuthorship W2610030900A5066979556 @default.
• W2610030900 hasAuthorship W2610030900A5080632338 @default.
• W2610030900 hasAuthorship W2610030900A5087135665 @default.
• W2610030900 hasBestOaLocation W26100309002 @default.
• W2610030900 hasConcept C121608353 @default.
• W2610030900 hasConcept C126322002 @default.
• W2610030900 hasConcept C143998085 @default.
• W2610030900 hasConcept C207103383 @default.
• W2610030900 hasConcept C2776694085 @default.
• W2610030900 hasConcept C2777292972 @default.
• W2610030900 hasConcept C2777802072 @default.
• W2610030900 hasConcept C2778220009 @default.
• W2610030900 hasConcept C2778239845 @default.
• W2610030900 hasConcept C2781209748 @default.
• W2610030900 hasConcept C44249647 @default.
• W2610030900 hasConcept C71924100 @default.
• W2610030900 hasConceptScore W2610030900C121608353 @default.
• W2610030900 hasConceptScore W2610030900C126322002 @default.
• W2610030900 hasConceptScore W2610030900C143998085 @default.
• W2610030900 hasConceptScore W2610030900C207103383 @default.
• W2610030900 hasConceptScore W2610030900C2776694085 @default.
• W2610030900 hasConceptScore W2610030900C2777292972 @default.
• W2610030900 hasConceptScore W2610030900C2777802072 @default.
• W2610030900 hasConceptScore W2610030900C2778220009 @default.
• W2610030900 hasConceptScore W2610030900C2778239845 @default.
• W2610030900 hasConceptScore W2610030900C2781209748 @default.
• W2610030900 hasConceptScore W2610030900C44249647 @default.
• W2610030900 hasConceptScore W2610030900C71924100 @default.
• W2610030900 hasIssue "6" @default.
• W2610030900 hasLocation W26100309001 @default.
• W2610030900 hasLocation W26100309002 @default.
• W2610030900 hasLocation W26100309003 @default.
• W2610030900 hasLocation W26100309004 @default.
• W2610030900 hasOpenAccess W2610030900 @default.
• W2610030900 hasPrimaryLocation W26100309001 @default.
• W2610030900 hasRelatedWork W1978427220 @default.

• next